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GAP trial
Abstract 
Objective: To measure the costs of a polypill strategy and compare them with 
those of usual care in people with established cardiovascular disease (CVD) or at 
similarly high cardiovascular risk.
Design: A within-trial cost analysis of polypill-based care versus usual care with 
separate medications, using data from the Kanyini Guidelines Adherence with 
the Polypill (GAP) trial and linked health service and medication administrative 
claims data.
Participants: Kanyini GAP participants who consented to Australian Medicare 
record access.
Main outcome measures: Mean health service and pharmaceutical expenditure 
per patient per year, estimated with generalised linear models. Costs during the 
trial (randomisation January 2010 – May 2012, median follow-up 19 months, 
maximum follow-up 36 months) were inflated to 2012 costs.
Results: Our analysis showed a statistically significantly lower mean 
pharmaceutical expenditure of $989 (95% CI, $648–$1331) per patient per 
year in the polypill arm compared with usual care (P < 0.001; adjusted, excluding 
polypill cost). No significant difference was shown in health service expenditure.
Conclusions: This study provides evidence of significant cost savings to the 
taxpayer and Australian Government through the introduction of a CVD polypill 
strategy. The savings will be less now than during the trial due to subsequent 
reductions in the costs of usual care. Nonetheless, given the prevalence of CVD 
in Australia, the introduction of this polypill could increase considerably the 
efficiency of health care expenditure in Australia.
Trial registration: Australian New Zealand Clinical Trials Registry 
ACTRN126080005833347.
 There is increasing global in-terest in the use of frequently indicated medications in 
fixed-dose combination for the pre-
vention of cardiovascular disease 
(CVD).1,2 Evidence of the effectiveness 
of such polypills as a strategy in im-
proving adherence to recommended 
treatment and potentially lowering 
costs is growing.3,4 Although there 
are combination blood pressure-
lowering and cholesterol-lowering 
medications, a more comprehensive 
cardiovascular polypill (containing 
generic aspirin, a lipid-lowering and 
two blood pressure-lowering agents) 
is not currently available in Australia. 
At a feasible cost of less than $1 per 
day5 compared with a minimum cost 
in Australia of $1.70 per day for in-
dividual generic therapies (http://
pbs.gov.au/info/about-the-pbs), 
prima facie evidence exists for ex-
tensive savings from such a strategy 
in Australia.
The cost-effectiveness of polypill-
based strategies compared with in-
dividual medications has yet to be 
tested in real-life settings, although 
cost-effectiveness has been shown in 
different patient groups and health 
care settings using modelled projec-
tions.5,6-8 For instance, based on a 
modelled analysis of high-risk pri-
mary care Dutch participants, poly-
pill use after opportunistic screening 
was cost-effective among people aged 
over 40 years.8 Similarly, a polypill 
strategy was found to be cost-ef-
fective and potentially cost-saving 
in older patients after myocardial 
infarction.7
This analysis is based on the 
Kanyini Guidelines Adherence with 
the Polypill (GAP) pragmatic ran-
domised controlled clinical trial and 
linked health service and medica-
tion administrative claims data from 
Medicare Australia. Kanyini GAP 
was pragmatic in that it was con-
ducted within the primary care set-
ting, with the study drug dispensed 
through community pharmacies, 
to test the effectiveness of a poly-
pill-based strategy in real-world 
practice.9 In the trial, the polypill 
improved patients’ adherence to 
treatment and there was no differ-
ence in mean blood pressure and 
cholesterol levels.3 The results were 
consistent with a larger sister trial, 
the UMPIRE (Use of a Multidrug 
Pill in Reducing Cardiovascular 
Events) study. Conducted in Europe 
and India, UMPIRE found that a 
polypill strategy yielded improve-
ments in self-reported adherence, 
along with statistically significant 
but small additional reductions in 
blood pressure and cholesterol, com-
pared with non-polypill treatment, in 
the polypill arm.4 A unique design 
feature of Kanyini GAP was that all 
medications, including the polypill, 
were dispensed at an out-of-pocket 
charge consistent with prevailing 
Medicare subsidies (around $35 per 
medication per month for general 
patients).
Methods
A within-trial cost analysis of the 
polypill strategy versus usual care 
was conducted from the Australian 
health system perspective (ie, govern-
ment plus patient costs). Kanyini GAP 
was carried out within Indigenous 
and non-Indigenous urban, rural, 
and remote primary care settings 
across Australia (randomisation from 
January 2010 to May 2012; median 
follow-up, 19 months; maximum 
follow-up, 36 months).3
Data on health service and medica-
tion expenditure throughout Kanyini 
GAP were obtained via individu-
ally linked Australian Medicare re-
cords for study participants who 
consented to linkage. Two separate 
Medicare datasets were analysed: the 
Medicare Benefits Schedule (MBS), 
which records government and pa-
tient costs of general practitioner 
and specialist visits and diagnostic 
tests; and the Pharmaceutical Benefits 
Scheme (PBS), which records the total 
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government and patient costs of all 
medications dispensed outside hos-
pital. The PBS data do not include 
polypill costs, as it is not marketed 
in Australia. As no difference was 
found in safety or clinical outcomes 
between treatment groups in the 
Kanyini GAP trial, we assumed 
no differences in hospital-related 
expenditure.
The primary outcome was mean 
MBS and PBS expenditure per pa-
tient per year. The base year for the 
analysis was 2012.10 This study was 
approved by human research eth-
ics committees in all relevant juris-
dictions (Sydney South West Area 
Health Service; Aboriginal Health 
and Medical Research Council of 
New South Wales; Cairns Base 
Hospital; Princess Alexandra 
Hospital Centres for Health Research; 
Central Australia; Northern Territory 
Department of Health and Menzies 
School of Health Research; Monash 
University). Each participant provid-
ed written informed consent.
Statistical analysis
Multivariable analysis was conducted 
to accommodate potential differ-
ences between treatment groups, 
given these analyses were restricted 
to the subset of trial participants 
consenting to Medicare linkage.11 
Non-significant demographic, socio-
economic, health and treatment-relat-
ed covariates (P > 0.10) were removed 
via backwards stepwise elimination. 
To account for the empirical distri-
bution of MBS and PBS cost data,11-14 
generalised linear models were used 
to estimate the primary outcome, and 
the marginal difference between 
treatment groups was compared 
(Wald test). Deb–Manning–Norton 
programs for Stata 12.1 (StataCorp) 
were used.12
Results
Box 1 and Box 2 detail the flow of pa-
tients through this analysis. Consent 
for linkage with MBS and PBS data 
was obtained from 93.9% (585/623) 
and 92.0% (573/623) of trial partici-
pants, respectively, and data were 
provided for 94.9% of participants 
(MBS, 555/585; PBS, 544/573). With 
regard to PBS data, 10.8% (62/573) 
of consenting participants were 
receiving medications under the 
special rural and remote access pro-
visions of section 100 of the National 
Health Act 1953 (Cwlth) and were re-
moved from this analysis, as these 
data were not captured by Medicare 
at an individual patient level (Box 2). 
There was no differential availabil-
ity of linked data between treatment 
groups.
The MBS and PBS expenditures 
by the Australian health system 
(government plus patient costs) 
per patient per year, excluding the 
cost of the polypill, are presented 
in Box 3. The adjusted analysis pre-
dicted a mean cost saving for phar-
maceutical expenditure of $989 (95% 
CI, $648–$1331) per patient per year 
(P < 0.001) to the health system. No 
significant differences were found 
in MBS expenditure.
Discussion
Our study showed that participants 
receiving polypill-based care had 
significantly lower pharmaceutical 
expenditure than usual care, with no 
difference in health service expendi-
ture. The overall potential savings 
are dependent on the reimbursement 
price of the polypill. Under current 
Australian guidelines, fixed-dose 
combinations such as the polypill 
are reimbursed at no greater than the 
sum of the costs of the generic com-
ponents,15 which was $1.70 per day 
at the time the trial was conducted. 
At this maximum price, and based 
on an average of 264 days per year 
on polypill treatment as observed 
in the treatment arm of the Kanyini 
GAP study,3 the annual savings to 
the health system would be $540 (ie, 
$989 − $1.70  264 days) per patient.
The Kanyini GAP trial found that 
the polypill was safe and effective in 
improving combination preventive 
treatment use by patients.3,4 Using 
primary care expenditure data, 
our within-trial analysis provides 
evidence of significant cost savings 
through the introduction of a CVD 
polypill, showing its economic domi-
nance over conventional individual 
therapies. The ACE Prevention pro-
ject, an Australian economic model-
ling study,5 also indicated dominance, 
estimating that a polypill at $200 per 
person per year was cost saving and 
resulted in a large population health 
impact, even when provided to pa-
tients at lower risk than those in the 
Kanyini GAP trial. If we had applied 
this lower cost in our analysis, we 
would have estimated annual health 
system savings of $789 per patient.
Challenges remain before large cost 
savings can be realised in Australia. 
First, no polypill has had regulatory 
approval in Australia to date. While 
several cardiovascular combinations 
have been approved, these are sim-
ple two-component combinations 
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1 Medicare Beneﬁ ts Schedule 
expenditure
585
Total number 
requested
30 (5.1%)
Rejected from
Medicare
555 (94.9%)
Accepted from
Medicare
551 (94.2%)
Claim made
4 (0.7%)
No claim made
270 Usual care2 Usual care
281 Polypill2 Polypill
2 Pharmaceutical Beneﬁ ts Scheme 
expenditure
573
Total number
requested
29  (5.1%)
Rejected from 
Medicare
544  (94.9%)
Accepted from 
Medicare
458 (79.9%)
Claim made
24 (4.2%)
No claim made
482 (84.1%)
Non-s. 100 sites
62 (10.8%)
s. 100 sites*
229 Usual care9 Usual care
229 Polypill15 Polypill
* Patients receiving medications under the 
special rural and remote access provisions; 
individual-level data not captured by 
Medicare.                                                                        
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approved on the basis of straight 
substitution among patients receiving 
recommended medications (among 
whom the benefits are smallest),3,4 
and have probably increased costs 
as a result of not being subject to au-
tomatic price reductions.16 Another 
challenge will be appropriate scale-
up while maintaining overall cost 
savings — large investments will 
be required in order to bring about 
practice change for this relatively new 
way of treating patients.
One limitation with using PBS data 
is that over-the-counter and very low-
cost medications priced at below the 
government copayment level are not 
captured. However, this potentially 
leads to an underestimate of the cost 
savings as it is likely to include some 
of the individual cardiovascular med-
icines in usual care, such as aspirin. 
Additionally, subsequent reductions 
in the cost of usual care associated 
with the expiry of patents for ator-
vastatin and rosuvastatin since con-
ducting the Kanyini GAP trial may 
have an impact on the translation of 
such cost savings into contemporary 
practice.
This is the first study using indi-
vidual patient-linked administrative 
data to evaluate the cost offsets as-
sociated with a CVD polypill com-
pared with current practice. Given 
that over 600 000 Australians at high 
risk of CVD are currently prescribed 
antiplatelet, blood pressure and lipid-
lowering medication, and a similar 
number are on partial treatment,17,18 
this polypill has the potential to not 
only help to reduce the large gaps 
that exist in Australia between rec-
ommended and actual treatment for 
patients with CVD,18 but also to free 
up considerable amounts of pharma-
ceutical expenditure .
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3 Health system expenditure (government plus patient costs) per patient per year of follow-up*
Scheme Usual care Polypill Marginal diff erence
Medicare Beneﬁ ts Schedule
No. of participants 270 281 –
Unadjusted expenditure, mean (95% CI) $1772 ($1581 to $1963) $1760 ($1602 to $1917) $13 (− $236 to $261)†
Adjusted‡ expenditure, mean (95% CI) $1767 ($1583 to $1951) $1770 ($1615 to $1926) $40 (− $202 to $281)
Pharmaceutical Beneﬁ ts Scheme
No. of participants 229 229 –
Unadjusted expenditure, mean (95% CI) $2438 ($2100 to $2775) $1443 ($1285 to $1601) $995 ($622 to $1368)†¶
Adjusted§ expenditure, mean (95% CI) $2448 ($2141 to $2754) $1446 ($1291 to $1602) $989 ($648 to $1331)†¶
* 2012 A$, estimated with generalised linear model (gamma family, log link). † In favour of polypill. ‡ Adjusted for sex, Australian rural and remote 
area index (http://www.aihw.gov.au/rural-health-rrma-classification), adherence at baseline, history of cardiovascular disease and prior medication 
use. § Adjusted for sex, Australian rural and remote area index, health care concession status–income interaction, adherence at baseline, history of 
cardiovascular disease and prior medication use. ¶ P < 0.001. 
